Biblio Discovery — Demo Discovery Service

209 results

Showing 1–20 · 0.19 seconds · RSS

Journal

Drugs in R&D

Scopus

ISSN 1174-5886 · Adis, Springer Healthcare · 209 articles in the index

  1. Journal Article

    Development and Optimization of a Biphasic-Release Acetazolamide Tablet-in-Tablet Formulation

    Si-kai Wang; Wei Li; Miao-miao Guo et al.

    Drugs in R&D, Vol. 26 No. 2 · 2026 · English · DOAJ Scopus

    Abstract Background and Objective High-altitude illness (HAI) poses health risks to individuals at high altitudes, and acetazolamide (ACZ) is the only Food and Drug Administration (FDA)-approved prophylactic drug. Conventional immediate-release (IR) tablets and extended-release (ER) capsules do not…

  2. Journal Article

    A Combination of the Tryptophan Hydroxylase Inhibitor Telotristat with the mTOR Inhibitor Everolimus as an Effective Strategy Against Neuroendocrine Tumors

    Javier Molina-Cerrillo; Arantzazu Sierra-Ramirez; José L. López-Aceituno et al.

    Drugs in R&D, Vol. 26 No. 2 · 2026 · English · DOAJ Scopus

    Abstract Background and Objectives Neuroendocrine tumors are a rare and heterogeneous group of neoplasms that frequently cause carcinoid syndrome, characterized by diarrhea, flushing, and carcinoid heart disease. A recent therapy for carcinoid syndrome involves inhibition of tryptophan hydroxylase…

  3. Journal Article

    Ustekinumab in the Management of Perianal Fistulizing Crohn’s Disease: Current Evidence and Practical Strategies

    Bolin Yang

    Drugs in R&D, Vol. 26 No. 2 · 2026 · English · DOAJ Scopus

    Abstract Perianal fistulizing Crohn’s disease (PFCD) is a severe and complex manifestation associated with high morbidity and limited treatment durability. Ustekinumab is a monoclonal antibody targeting the interleukin-12/23 pathway, which is involved in the pathogenesis of PFCD. Evidence from post…

  4. Journal Article

    Gabapentin Extended Release Tablets in Healthy Subjects Under Fed Conditions: A Randomized, Open-Label, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Crossover, Comparative Bioavailability Study

    Sudershan Kumar; Arshad Khuroo; Sanjay Jagannath Gurule et al.

    Drugs in R&D, Vol. 26 No. 2 · 2026 · English · DOAJ Scopus

    Abstract Background Gabapentin is effective for treating post-herpetic neuralgia and neuropathic pain by stabilizing nerve activity through blocking calcium channels and reducing neurotransmitter release. Gabapentin is available in immediate-release (IR) and extended-release (ER) formulations. A…

  5. Journal Article

    HIF-1α siRNA Enhances the Efficacy of Erlotinib in Non-small Cell Lung Cancer: A Novel Strategy to Reverse Hypoxia-Induced Drug Resistance

    Haojie Jiang; Shunhui Cai; Xiaojun Zhang et al.

    Drugs in R&D, Vol. 26 No. 1 · 2026 · English · DOAJ Scopus

    Abstract Background Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality. While EGFR tyrosine kinase inhibitors (EGFR-TKIs) have improved survival, acquired resistance mediated by tumor hypoxia and HIF-1α stabilization often leads to treatment failure. This study…

  6. Journal Article

    Advanced Drug Delivery Strategies for Overcoming Biological Barriers: Tumor Microenvironment and Blood–Brain Barrier

    Yicong Lei; Tingyu Xiao; Xin Hu et al.

    Drugs in R&D, Vol. 26 No. 1 · 2026 · English · DOAJ Scopus

    Abstract Therapeutic efficacy for malignancies and neurological disorders is fundamentally restricted by biological barriers, particularly the complex tumor microenvironment (TME) and selective blood–brain barrier (BBB). This review analyzes advanced drug delivery technologies engineered to…

  7. Journal Article

    The Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Iclepertin (BI 425809): Results from Two Phase I Open-Label, Non-randomised, Single Dose, Parallel Design Studies

    HeeJae Choi; Shilpa Madari; Elmar Daalman et al.

    Drugs in R&D, Vol. 26 No. 1 · 2026 · English · DOAJ Scopus

    Abstract Background and Objectives Iclepertin, a selective GlyT1 inhibitor undergoes metabolism mainly via hepatic CYP3A4, with only a small fraction undergoing urinary excretion. Patients with kidney or liver problems can have reduced CYP3A4 levels or activity, which may affect the levels of…

  8. Journal Article

    Development and Evaluation of Multiple-Unit Tablets for the Controlled Release of Lornoxicam

    Yang Liu; Qiong-zhi Shi; Yanchen Wang et al.

    Drugs in R&D, Vol. 26 No. 1 · 2026 · English · DOAJ Scopus

    Abstract Background and Objective Lornoxicam (LOX) is a nonsteroidal anti-inflammatory drug used for pain management but requires frequent dosing due to its short half-life. This study aimed to develop a biphasic-release multiple-unit tablet (MUT) to achieve rapid and sustained LOX release with…

  9. Journal Article

    Arylpiperazine Derivative NAF19 Inhibits Prostate Cancer Activity and Its Molecular Mechanisms

    Hua Jiang; Mingzhen Xu; Songsong Jiang et al.

    Drugs in R&D, Vol. 26 No. 1 · 2026 · English · DOAJ Scopus

    Abstract Background and Objectives Androgen deprivation therapy (ADT) remains the primary treatment for advanced prostate cancer. However, most patients relapse within 18–24 months, progressing to castration-resistant prostate cancer (CRPC) which is currently incurable. Our preliminary studies…

  10. Journal Article

    Pharmacokinetics and Bioequivalence Evaluation of Piracetam Tablet: A Randomized, Single-Dose, Two-Period, Crossover Study in Healthy Chinese Participants Under Fasting and Fed Conditions

    Hegui Yan; Ming Zhou; Zhixiang Pan et al.

    Drugs in R&D, Vol. 26 No. 1 · 2026 · English · DOAJ Scopus

    Abstract Background Piracetam, a nootropic drug, is widely used for treating cognitive impairments. However, pharmacokinetic and bioequivalence data for piracetam formulations in the Chinese population are limited. This study was conducted to evaluate the pharmacokinetics and bioequivalence of a…

  11. Journal Article

    Updated Viloxazine Pharmacology: Experiments Establish Norepinephrine Transporter Occupancy and Serotonin 5-HT2C, 5-HT2B, and 5-HT7 Receptor Binding at Therapeutically Relevant Concentrations

    Jennie Garcia-Olivares; Brittney Yegla; Jennifer Koch et al.

    Drugs in R&D, Vol. 26 No. 1 · 2026 · English · DOAJ Scopus

    Abstract Background and Objectives Viloxazine, which has been used to treat depression and attention-deficit/hyperactivity disorder (ADHD), has been termed a moderate-affinity, selective norepinephrine reuptake inhibitor based on high selectivity for norepinephrine relative to serotonin and…

  12. Journal Article

    Preclinical Evaluation of AHT-102, a CLDN18.2 × CD3 Bispecific Antibody: Pharmacokinetics, Anti-Tumor Efficacy, Tissue Distribution, and Safety Profile

    Huilun Chu; Guili Xu; Yunlong Liu et al.

    Drugs in R&D, Vol. 26 No. 1 · 2026 · English · DOAJ Scopus

    Abstract Background and Objectives Claudin18.2 (CLDN18.2) is a promising therapeutic target overexpressed in various tumor tissues. While CD3-engaging bispecific antibodies show great potential, their clinical application is often limited by poor efficacy in solid tumors and significant safety…

  13. Journal Article

    Drugs for Procedural Sedation and Analgesia in Children: A Systematic Review and Meta-analysis

    Sandrella Hamdan; Samuel Adelou; Sébastien Jungo et al.

    Drugs in R&D, Vol. 25 No. 3 · 2025 · English · DOAJ Scopus

    Abstract Background and Objectives Performing medical procedures on children can often be challenging because of the anxiety that these procedures may induce, the need for immobility that they may require, or age-related development capabilities. We assessed the effects of procedural sedation and…

  14. Journal Article

    In-Vitro Comparison of Physical Characteristics, Enzyme Content, and Release Kinetics of Pancreatic Enzyme Preparations Available in Europe and Canada

    Sven Hartmann; Jonas Rosendahl; Amy Todd et al.

    Drugs in R&D, Vol. 25 No. 3 · 2025 · English · DOAJ Scopus

    Abstract Introduction Commercially available pancreatic enzyme replacement therapy (PERT) preparations differ significantly in their physical and enzyme properties, raising concern about the interchangeability of these preparations. The current study aimed to compare various commercially available…

  15. Journal Article

    Effect of Severe Renal Impairment on Dordaviprone (ONC201) Pharmacokinetics

    Shamia L. Faison; Joelle Batonga; Thangam Arumugham et al.

    Drugs in R&D, Vol. 25 No. 3 · 2025 · English · DOAJ Scopus

    Abstract Background and Objective Dordaviprone (ONC201) is a novel small molecule with antitumor effects in patients with glioma. The major elimination pathway of dordaviprone is metabolism via cytochrome P450 (CYP) 3A4. This study was designed to assess the effect of severe renal impairment (RI)…

  16. Journal Article

    Demonstrating Bioequivalence for a Lumacaftor Monosubstance Formulation Versus Orkambi® (Lumacaftor/Ivacaftor) in Healthy Subjects

    Alexandra Papaelias; Darcy Lidington; Steffen-Sebastian Bolz

    Drugs in R&D, Vol. 25 No. 3 · 2025 · English · DOAJ Scopus

    Abstract Background and Objective Lumacaftor is an active ingredient in the US Food and Drug Administration-approved combination medication Orkambi®, which is used for treating cystic fibrosis. Experimental evidence suggests that lumacaftor can be used as a monotherapy to improve brain perfusion…

  17. Journal Article

    Pharmacokinetic Comparison of Novel Tablet-in-Tablet and Conventional Ketorolac Tromethamine Tablets in Beagle Dogs

    Xiang-yang Xie; Yuan Zeng; Zhi-long Chen et al.

    Drugs in R&D, Vol. 25 No. 3 · 2025 · English · DOAJ Scopus

    Abstract Background and Objective Ketorolac tromethamine (KT), a nonsteroidal anti-inflammatory drug (NSAID) and cyclooxygenase inhibitor, is commonly used for the management of moderate to severe pain. The objective of this study was to compare the pharmacokinetic characteristics of KT in beagle…